HeartBeam Reports Second Quarter 2026 Results
HeartBeam reported second quarter 2026 results with a net loss of $5.0 million, or $0.10 per share, while highlighting the start of its commercial launch and ahead-of-schedule progress in clinical trials. The company strengthened its balance sheet to $8.7 million in cash following an April offering and reduced its net operating cash outflow guidance to below $14.0 million for the full year. Operational milestones included completing enrollment in the ALIGN-ACS pilot study and shipping first orders for the HeartBeam System in four targeted U.S.
Key figures
- Guidance
- Full year 2026 net operating cash outflow expected to be below $14.0 million
- Net loss q2
- 5000000
- Cash position
- 8700000
- Patents issued
- 26
- Operating expenses q2
- 5100000
- Offering proceeds april
- 11500000
- Net operating cash used q2
- 3300000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.